Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
131I-Sibrotuzumab in advanced NSCLC
NCT02209727Phase 1Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Dec 2000
- Primary completion
- Jun 2002
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, open-label, single-arm trial of 131I-sibrotuzumab in non-small cell lung cancer (NSCLC), sponsored by Boehringer Ingelheim. Primary endpoints: Dose Limiting Toxicity at 12 weeks, Maximum Tolerated Dose at 12 weeks and 1 more. Started Dec 2000; status: terminated.
02
Drugs
131I-sibrotuzumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02209727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02209727.